A Phase 3 interventional study of Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) and Pertuzumab IV in Early Breast Cancer, Locally Advanced Breast Cancer and Inflammatory Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 45 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer.
112 studies on the registry are indexed under Inflammatory Breast Neoplasms; 7 are open to participants now.
This study's enrollment of 346 is above the median of 58 across 96 interventional studies indexed under Inflammatory Breast Neoplasms.
Browse Inflammatory Breast Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Inflammatory Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease-specific Inclusion Criteria:
Inclusion Criteria for Treatment with Adjuvant PH FDC SC:
Exclusion Criteria:
Cancer-specific Exclusion Criteria for Phase:
Exclusion Criterion for Treatment with Adjuvant Trastuzumab Emtansine (Arm E):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with pertuzumab and trastuzumab intravenously (PH IV) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH IV will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH IV will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
Drug: Pertuzumab IV · Drug: Trastuzumab IV · Drug: Investigator's Choice of Chemotherapy · Procedure: Surgery · Radiation: Radiotherapy
During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with the fixed dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH FDC SC will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH FDC SC will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) · Drug: Investigator's Choice of Chemotherapy · Procedure: Surgery · Radiation: Radiotherapy
During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm C will receive 3 cycles of PH FDC SC in the hospital and then 3 cycles of PH FDC SC in the home setting. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm D will receive 3 cycles of PH FDC SC in the home setting and then 3 cycles of PH FDC SC in the hospital. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Participants with pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy and surgery will enter Arm E to receive trastuzumab emtansine for 14 cycles. Trastuzumab emtansine will be administered IV in the hospital as per prescribing information.
Drug: Trastuzumab Emtansine
Drug page: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
Also known as: PHESGO®, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, RO7198574, RG6264
Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
Also known as: Perjeta®, RO4368451
Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
Also known as: Herceptin®, RO0452317
Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
Also known as: Kadcyla®, ado-trastuzumab emtansine, T-DM1, RO5304020
Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)
The PPQ was used to evaluate the participant preference for PH FDC SC compared to P+H IV. Participants completed the PPQ, where Question (Q) 1 was: "All things considered, which setting for your treatment did you prefer?" Participants were required to select one of the following options: home, hospital or no preference. The reported results show the percentage of participants who preferred receiving PH FDC SC at home setting over the hospital setting. Percentages were rounded off.
Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 1a of HCPQ - Drug Preparation Area
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1a: "Please indicate which treatment preparation the estimates relate to". HCPs were required to select one of the following options: PH FDC SC or P+H IV. The response to Q1a was used to further assess Q1b: How long did it take to prepare the treatment for use? Percentages were rounded off.
Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)
Neoadjuvant Phase: Duration of Treatment Preparation, According to Healthcare Professionals' Responses to Question 1b of HCPQ - Drug Preparation Area
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1b: "How long did it take to prepare the treatment for use?" This was a follow up question to Q1a: "Please indicate which treatment preparation the estimates relate to" for which HCPs were required to select one of the following options: PH FDC SC or P+H IV.
Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 of the HCPQ - Drug Preparation Area
HCP=any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question 2 of the HCPQs: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Staff will have increased availability for other tasks in the pharmacy. 2b: Administrative procedures related to PH FDC SC require less time. 2c: Using PH FDC SC provides more flexibility for pharmacy staff in managing their workload. 2d: As PH FDC SC is fixed-dose, potential dosing errors are avoided. 2e: As PH FDC SC is fixed-dose, there is less drug wastage. 2f: Less storage space for PH FDC SC-related supplies is required in the pharmacy, as there is no need for reconstitution. 2g: Number of preparation steps \& staff time commitment are reduced. Percentages were rounded off.
Time frame: Up to Day 1 of Cycle 8 (Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Questions 1a-1e of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1a: Please indicate which treatment preparation the estimates relate to. Q1b: Did the participant have existing IV access? Q1c: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided. Q1d: What type of existing IV access did the participant have? Q1e: When did the existing IV access place? Percentages were rounded off. PICC = peripherally inserted central catheter.
Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)
Neoadjuvant Phase: Duration of Treatment Administration According to HCPs' Responses to Questions 1c (Sub-part), 1f, and 1g of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1c: If new IV access was needed for this cycle of treatment, how long (in minutes) this took to set up? Q1f: How long (in minutes) did it take to administer the treatment (P+H IV or PH FDC SC)? Q1g: How long (in minutes) was the participant in the Treatment Area in total? Percentages have been rounded off.
Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 (2a to 2e) of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Q2 (2a-2e) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Participants may be moved out of the Treatment Area (for infusion treatment) to receive PH FDC SC injections. 2b: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2c: Frees up infusion chairs for participants whose treatments can only be given IV. 2d: Waiting list for any P+H IV treatment at the Treatment Area is reduced. 2e: Staff's work burden is reduced, enhancing work performance. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.
Time frame: Up to Cycle 8 (Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 2 (2f to 2j) of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Question 2 (2f to 2j) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2f: More interaction time between HCPs and participants. 2g: Staff have more time for further professional education/development. 2h: Staff has more time for administrative tasks. 2i: Participants on PH FDC SC spend less time in the Treatment Area. 2j: Participants prefer PH FDC SC to P+H IV. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.
Time frame: Up to Cycle 8 (Cycle length = 21 days)
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 3 to 11 of the HCPQ - Administering Treatment
HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Questions 3 to 11 of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care at your institution? Q5: Which required less time to administer (excluding observation period)? Q6: Which required less use of institutional resources (e.g., staff time, facility costs, equipment use)? Q7: Which required less time to administer all the treatment (including IV chemotherapy)? Q8: Which allowed for attending to more participants because of time savings from the mode of administration of pertuzumab and trastuzumab? Q9: During the NP you had to administer IV chemotherapy through participant's IV access. You prefer to accompany IV chemotherapy with? Q10: Which was preferred by participants? Q11: How frequently would you recommend PH FDC SC administration to your participants in the future? Percentages were rounded off.
Time frame: Up to Cycle 8 (Cycle length = 21 days)
Percentage of Participants Who Achieved pCR Post-surgery
pCR was defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0), according to the current American Joint Committee on Cancer (AJCC) staging system classification. Percentages were rounded off.
Time frame: Up to approximately 7.8 months
Neoadjuvant Phase: Change From Baseline in Health-related Quality of Life (HRQoL) Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) Scores
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), global health status/quality of life (GHS/QoL) \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
Time frame: Baseline, Day 1 of Cycles 6 and 8 (Cycle length = 21 days)
Adjuvant Phase: Change From Baseline in HRQoL Assessed by EORTC QLQ C30 Scores
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
Time frame: Baseline (Cycle 1) of Run-in Period; Day 1 of Cycles 1, 3, and 6 in the Cross-over Period (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1a and 1c of the HCPQ - Drug Preparation Area
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: Where was the treatment prepared? Q1c: Which healthcare professionals were involved in the treatment preparation processes? The 4 available response options for Q1a were: Participant's home, Hospital pharmacy, Day oncology unit, or Other. The 5 available response options for Q1c were: Physician, Nurse, Pharmacist, All of them or Other. Percentages were rounded off.
Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Duration of Treatment Preparation, According to HCPs' Responses to Question 1b of the HCPQ - Drug Preparation Area
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following parts of question Q1b: Q1b(1): How long did it take to prepare the treatment for use? Q1b(2): Time from the preparation place to reach the participant's home.
Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 2, 3 and 4 of the HCPQ - Drug Preparation Area
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the questions 2, 3 and 4 of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant´s home, please indicate how strongly you agree or disagree with each of the following statements: 2a: Staff will have increased availability for other tasks in the hospital´s pharmacy. 2b: Administrative procedures related to PH FDC SC will require less time. 2c: Number of preparation steps and staff time commitment are reduced. The 5 response options were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree or Not applicable. Q3: Which took less time? Q4: Which required less use of institutional resources? The 4 available options were: Participant's home, In hospital, No difference, or Unsure. Percentages were rounded off.
Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Duration of Administering Treatment, According to HCPs' Responses to Question 1a to 1f of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: How long did it take to travel to the participant's home to administer PH FDC SC? Q1b: How long did it take for the participant to travel to the hospital to receive PH FDC SC? Q1c: How long did it take to administer PH FDC SC? Q1d: How long was the participant treatment time? Q1e: How much time did the participant spend in hospital? Q1f: How much time did you spend at the participant's home? From arrival to departure time.
Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1g, 1h, and 1i of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1g. Does the participant still have implanted IV access? The 2 available responses were: Yes or No. Q1h: If question 1g was answered 'No', when was the IV access removed? The 3 available responses were: After surgery and before initiating adjuvant treatment; After initiating adjuvant treatment, or Not applicable. Q1i: If question 1g was answered 'Yes', what is the main reason to keep the IV access? The 5 available responses were: Local protocol; Risk of recurrence; Participant preference; Not applicable, or Other. Percentages were rounded off.
Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1j, 1k, and 1l of the HCPQ - Administering Treatment
HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1j: How long do you keep implanted IV access in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer participants with pCR following surgery in your institution? The 5 available responses were: \<12 months, ≥12 months, 18 months, \<24 months, ≥24 months. Q1k: When is the decision point for you to decide to remove IV access for early HER2+ breast cancer participants? The 6 available responses were: Before surgery, After surgery, After PCR results, After completion of full adjuvant therapy, After completion of IV antineoplastic within adjuvant therapy, and Other. Q1l: Do you consider it necessary to keep implanted IV access knowing that the participant's treatment will be SC until the full 18 cycles? The 3 available responses were: Yes, No, and Unsure. Percentages were rounded off.
Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Question 2 of the HCPQ - Administering Treatment
HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following question of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant's home, please indicate how strongly you agree/disagree with each of the following statements: 2a: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2b: Frees up infusion chairs or outpatient procedure rooms used to administer SC injections. 2c: Waiting list for infusion chairs or outpatient procedure rooms is reduced. 2d: Staff's work burden is reduced, enhancing work performance. 2e: More interaction time between HCPs and participants on IV treatment. 2f: Staff has more time for administrative tasks. 2g: Participants will spend less time in hospital. 2h: Participants prefer PH FDC SC at home. The 6 available responses were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree, \& Not applicable.
Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 3 to 7 of the HCPQ - Administering Treatment
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care? Q5: Which required less use of institutional resources? Q6: Which was preferred by participants? The 4 responses available were: Participant's home, In hospital, No difference, and Unsure. Q7: How frequently would you recommend PH FDC SC at home to your participants in the future? The 3 responses available were: Always, Sometimes, and Never. Percentages were rounded off.
Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)
Adjuvant Phase: HRQoL Assessed by EORTC QLQ C30 Scores in Participants Treated With Trastuzumab Emtansine IV
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
Time frame: Day 1 of Cycles 1 and 6 (1 Cycle = 21 days)
Percentage of Participants Who Selected the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in the Treatment Continuation Period
The percentage of participants who chose to receive PH FDC SC in the home setting or in the hospital setting during the treatment continuation period is reported.
Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)
Neoadjuvant Phase: Number of Participants With Adverse Events (AEs), Grade ≥ 3 AEs, Serious AEs (SAEs), and Cardiac AEs
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in left ventricular ejection fraction (LVEF) of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; congestive heart failure (CHF). AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 7.4 months)
Neoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.
Time frame: Up to Cycle 8 (1 Cycle = 21 days)
Adjuvant Cross-over Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 5.8 months)
Adjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.
Time frame: Up to Cycle 6 (Cycle length = 21 days)
Treatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 3.5 years)
Treatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With Premature Withdrawal From PH FDC SC and Trastuzumab Emtansine IV Due to AEs
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinue study due to AEs will be reported.
Time frame: From initiation of study treatment in the adjuvant phase until 28 days after the last treatment cycle (up to approximately 3.5 years)
A total of 347 participants (1 participant was re-randomized to the same PH FDC SC arm) with early or locally advanced or inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer took part in the study at 45 investigative sites across 17 countries. The study is still ongoing. The health care professionals (HCPs) treating the participants were not enrolled in the study. The HCPs only completed the HCP questionnaire (HCPQ).
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 116 | 231 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neoadjuvant safety analysis set (sasab) | 115 | 228 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed neoadjuvant treatment | 114 | 210 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed surgery | 113 | 207 | 0 | 0 | 0 | 0 | 0 | 0 |
| Continued into the run-in period | 68 | 126 | 0 | 0 | 0 | 0 | 0 | 0 |
| Continued into trastuzumab emtansine iv arm | 43 | 74 | 0 | 0 | 0 | 0 | 0 | 0 |
| Switched from iv to sc treatment | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 111 | 200 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Treatment intolerance | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 194 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 194 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 98 | 96 | 0 | 0 | 0 |
| Received ≥1 dose of adjuvant cross-over treatment | 0 | 0 | 0 | 97 | 96 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 96 | 93 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Treatment intolerance | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 96 | 93 | 0 |
| Chose home setting for continuation treatment | 0 | 0 | 0 | 0 | 0 | 66 | 50 | 0 |
| Chose hospital setting for continuation treatment | 0 | 0 | 0 | 0 | 0 | 30 | 42 | 0 |
| Received ≥1 dose of continuation treatment | 0 | 0 | 0 | 0 | 0 | 96 | 89 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 82 | 81 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 14 | 12 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing in treatment | 0 | 0 | 0 | 0 | 0 | 11 | 9 | 0 |
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 117 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Treatment intolerance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Ongoing in treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 |
| Milestone | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital | Arm C, Adjuvant Continuation Phase: PH FDC SC | Arm D, Adjuvant Continuation Phase: PH FDC SC | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 85 | 87 | 87 |
| Completed | 0 | 0 | 0 | 0 | 0 | 40 | 40 | 34 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 45 | 47 | 53 |
| Withdrew: Ongoing in follow-up | 0 | 0 | 0 | 0 | 0 | 44 | 45 | 51 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
The PPQ was used to evaluate the participant preference for PH FDC SC compared to P+H IV. Participants completed the PPQ, where Question (Q) 1 was: "All things considered, which setting for your treatment did you prefer?" Participants were required to select one of the following options: home, hospital or no preference. The reported results show the percentage of participants who preferred receiving PH FDC SC at home setting over the hospital setting. Percentages were rounded off.
| percentage of participants | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Home | 69.0 | 59.0 |
| Hospital | 23.0 | 39.8 |
| No Preference | 8.0 | 1.2 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1a: "Please indicate which treatment preparation the estimates relate to". HCPs were required to select one of the following options: PH FDC SC or P+H IV. The response to Q1a was used to further assess Q1b: How long did it take to prepare the treatment for use? Percentages were rounded off.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Cycle 1 Day 1: PH FDC SC | 0 | 100 |
| Cycle 1 Day 1: P+H IV | 100 | 0 |
| Cycle 2 Day 1: PH FDC SC | 0 | 100 |
| Cycle 2 Day 1: P+H IV | 100 | 0 |
| Cycle 3 Day 1: PH FDC SC | 0 | 100 |
| Cycle 3 Day 1: P+H IV | 100 | 0 |
| Cycle 4 Day 1: PH FDC SC | 1.6 | 100 |
| Cycle 4 Day 1: P+H IV | 98.4 | 0 |
| Cycle 5 Day 1: PH FDC SC | 0.9 | 100 |
| Cycle 5 Day 1: P+H IV | 99.1 | 0 |
| Cycle 6 Day 1: PH FDC SC | 0.9 | 100 |
| Cycle 6 Day 1: P+H IV | 99.1 | 0 |
| Cycle 7 Day 1: PH FDC SC | 0 | 100 |
| Cycle 7 Day 1: P+H IV | 100 | 0 |
| Cycle 8 Day 1: PH FDC SC | 0 | 100 |
| Cycle 8 Day 1: P+H IV | 100 | 0 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1b: "How long did it take to prepare the treatment for use?" This was a follow up question to Q1a: "Please indicate which treatment preparation the estimates relate to" for which HCPs were required to select one of the following options: PH FDC SC or P+H IV.
| minutes | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Cycle 1 Day 1 | 20.0 (1 to 120) | 5.0 (0 to 30) |
| Cycle 2 Day 1 | 20.5 (1 to 50) | 5.0 (0 to 40) |
| Cycle 3 Day 1 | 20.0 (1 to 50) | 5.0 (1 to 35) |
| Cycle 4 Day 1 | 20.0 (1 to 50) | 5.0 (1 to 30) |
| Cycle 5 Day 1 | 20.0 (1 to 110) | 5.0 (1 to 52) |
| Cycle 6 Day 1 | 20.0 (1 to 410) | 5.0 (1 to 131) |
| Cycle 7 Day 1 | 13.5 (4 to 90) | 4.0 (1 to 45) |
| Cycle 8 Day 1 | 15.0 (4 to 90) | 5.0 (1 to 45) |
HCP=any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question 2 of the HCPQs: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Staff will have increased availability for other tasks in the pharmacy. 2b: Administrative procedures related to PH FDC SC require less time. 2c: Using PH FDC SC provides more flexibility for pharmacy staff in managing their workload. 2d: As PH FDC SC is fixed-dose, potential dosing errors are avoided. 2e: As PH FDC SC is fixed-dose, there is less drug wastage. 2f: Less storage space for PH FDC SC-related supplies is required in the pharmacy, as there is no need for reconstitution. 2g: Number of preparation steps \& staff time commitment are reduced. Percentages were rounded off.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Q2a: Strongly Disagree | 1.1 | 2.4 |
| Q2a: Disagree | 3.4 | 2.4 |
| Q2a: Neutral | 13.5 | 11.0 |
| Q2a: Agree | 25.8 | 38.4 |
| Q2a: Strongly Agree | 52.8 | 39.6 |
| Q2a: Not Applicable | 3.4 | 6.1 |
| Q2b: Strongly Disagree | 4.5 | 2.4 |
| Q2b: Disagree | 12.4 | 15.2 |
| Q2b: Neutral | 13.5 | 14.6 |
| Q2b: Agree | 18.0 | 25.6 |
| Q2b: Strongly Agree | 47.2 | 35.4 |
| Q2b: Not Applicable | 4.5 | 6.7 |
| Q2c: Strongly Disagree | 1.1 | 1.2 |
| Q2c: Disagree | 4.5 | 2.4 |
| Q2c: Neutral | 11.2 | 14.0 |
| Q2c: Agree | 28.1 | 41.5 |
| Q2c: Strongly Agree | 50.6 | 34.1 |
| Q2c: Not Applicable | 4.5 | 6.7 |
| Q2d: Strongly Disagree | 1.1 | 1.2 |
| Q2d: Disagree | 2.2 | 2.4 |
| Q2d: Neutral | 2.2 | 7.9 |
| Q2d: Agree | 28.1 | 36.0 |
| Q2d: Strongly Agree | 61.8 | 46.3 |
| Q2d: Not Applicable | 4.5 | 6.1 |
| Q2e: Strongly Disagree | 1.1 | 1.2 |
| Q2e: Disagree | 3.4 | 3.7 |
| Q2e: Neutral | 1.1 | 6.1 |
| Q2e: Strongly Agree | 31.5 | 35.4 |
| Q2e: Agree | 58.4 | 47.6 |
| Q2e: Not Available | 4.5 | 6.1 |
| Q2f: Strongly Disagree | 1.1 | 1.2 |
| Q2f: Disagree | 5.6 | 6.1 |
| Q2f: Neutral | 10.1 | 12.2 |
| Q2f: Strongly Agree | 24.7 | 33.5 |
| Q2f: Agree | 53.9 | 40.9 |
| Q2f: Not available | 4.5 | 6.1 |
| Q2g: Strongly Disagree | 1.1 | 1.8 |
| Q2g: Disagree | 7.9 | 4.2 |
| Q2g: Neutral | 7.9 | 6.1 |
| Q2g: Strongly Agree | 23.6 | 36.4 |
| Q2g: Agree | 56.2 | 44.8 |
| Q2g: Not available | 3.4 | 6.7 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1a: Please indicate which treatment preparation the estimates relate to. Q1b: Did the participant have existing IV access? Q1c: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided. Q1d: What type of existing IV access did the participant have? Q1e: When did the existing IV access place? Percentages were rounded off. PICC = peripherally inserted central catheter.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Cycle 1 Day 1: Q1a: PH FDC SC | 0 | 100 |
| Cycle 1 Day 1: Q1a: P+H IV | 100 | 0 |
| Cycle 1 Day 1: Q1b: Yes | 24.2 | 0 |
| Cycle 1 Day 1: Q1b: No | 75.8 | 100 |
| Cycle 1 Day 1: Q1c: Peripheral Vein Cannulation | 90.7 | 100 |
| Cycle 1 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 1 Day 1: Q1c: Central Venous Catheter | 9.3 | 0 |
| Cycle 1 Day 1: Q1d: Central Venous Catheter | 40.0 | 0 |
| Cycle 1 Day 1: Q1d: PICC | 33.3 | 50.0 |
| Cycle 1 Day 1: Q1d: Port-a-Cath | 26.7 | 50.0 |
| Cycle 1 Day 1: Q1d: Tunneled Central Venous Catheter | 0 | 0 |
| Cycle 1 Day 1: Q1e: Within 7 Days Prior Today | 50.0 | 16.7 |
| Cycle 1 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 33.3 |
| Cycle 1 Day 1: Q1e: > 14 < 30 Days Prior Today | 0 | 0 |
| Cycle 1 Day 1: Q1e: Other | 50.0 | 50.0 |
| Cycle 2 Day 1: Q1a: PH FDC SC | 0 | 100 |
| Cycle 2 Day 1: Q1a: P+H IV | 100 | 0 |
| Cycle 2 Day 1: Q1b: Yes | 23.0 | 60.0 |
| Cycle 2 Day 1: Q1b: No | 77.0 | 40.0 |
| Cycle 2 Day 1: Q1c: Peripheral Vein Cannulation | 88.6 | 66.7 |
| Cycle 2 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 2 Day 1: Q1c: Central Venous Catheter | 11.4 | 33.3 |
| Cycle 2 Day 1: Q1d: Central Venous Catheter | 35.7 | 40.0 |
| Cycle 2 Day 1: Q1d: PICC | 28.6 | 20.0 |
| Cycle 2 Day 1: Q1d: Port-a-Cath | 35.7 | 40.0 |
| Cycle 2 Day 1: Q1d: Tunneled Central Venous Catheter | 0 | 0 |
| Cycle 2 Day 1: Q1e: Within 7 Days Prior Today | 0 | 0 |
| Cycle 2 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 0 |
| Cycle 2 Day 1: Q1e: > 14 < 30 Days Prior Today | 16.7 | 62.5 |
| Cycle 2 Day 1: Q1e: Other | 83.3 | 37.5 |
| Cycle 3 Day 1: Q1a: PH FDC SC | 0 | 100 |
| Cycle 3 Day 1: Q1a: P+H IV | 100 | 0 |
| Cycle 3 Day 1: Q1b: Yes | 26.2 | 100 |
| Cycle 3 Day 1: Q1b: No | 73.8 | 0 |
| Cycle 3 Day 1: Q1c: Peripheral Vein Cannulation | 88.1 | 100 |
| Cycle 3 Day 1: Q1c: PICC | 2.4 | 0 |
| Cycle 3 Day 1: Q1c: Central Venous Catheter | 9.5 | 0 |
| Cycle 3 Day 1: Q1d: Central Venous Catheter | 33.3 | 57.1 |
| Cycle 3 Day 1: Q1d: PICC | 33.3 | 28.6 |
| Cycle 3 Day 1: Q1d: Port-a-Cath | 33.3 | 14.3 |
| Cycle 3 Day 1: Q1d: Tunneled Central Venous Catheter | 0 | 0 |
| Cycle 3 Day 1: Q1e: Within 7 Days Prior Today | 16.7 | 16.7 |
| Cycle 3 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 8.3 |
| Cycle 3 Day 1: Q1e: > 14 < 30 Days Prior Today | 0 | 25.0 |
| Cycle 3 Day 1: Q1e: Other | 83.3 | 50.0 |
| Cycle 4 Day 1: Q1a: PH FDC SC | 1.6 | 100 |
| Cycle 4 Day 1: Q1a: P+H IV | 98.4 | 0 |
| Cycle 4 Day 1: Q1b: Yes | 32.2 | 50.0 |
| Cycle 4 Day 1: Q1b: No | 67.8 | 50.0 |
| Cycle 4 Day 1: Q1c: Peripheral Vein Cannulation | 89.7 | 50.0 |
| Cycle 4 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 4 Day 1: Q1c: Central Venous Catheter | 10.3 | 50.0 |
| Cycle 4 Day 1: Q1d: Central Venous Catheter | 30.0 | 50.0 |
| Cycle 4 Day 1: Q1d: PICC | 35.0 | 0 |
| Cycle 4 Day 1: Q1d: Port-a-Cath | 35.0 | 50.0 |
| Cycle 4 Day 1: Q1d: Tunneled Central Venous Catheter | 0 | 0 |
| Cycle 4 Day 1: Q1e: Within 7 Days Prior Today | 0 | 7.7 |
| Cycle 4 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 0 |
| Cycle 4 Day 1: Q1e: > 14 < 30 Days Prior Today | 14.3 | 38.5 |
| Cycle 4 Day 1: Q1e: Other | 85.7 | 53.8 |
| Cycle 5 Day 1: Q1a: PH FDC SC | 0.9 | 100 |
| Cycle 5 Day 1: Q1a: P+H IV | 99.1 | 0 |
| Cycle 5 Day 1: Q1b: Yes | 33.3 | 25.0 |
| Cycle 5 Day 1: Q1b: No | 66.7 | 75.0 |
| Cycle 5 Day 1: Q1c: Port-a-cath | 1.4 | 0 |
| Cycle 5 Day 1: Q1c: Peripheral Vein Cannulation | 93.2 | 83.3 |
| Cycle 5 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 5 Day 1: Q1c: Central Venous Catheter | 5.5 | 16.7 |
| Cycle 5 Day 1: Q1d: Central Venous Catheter | 19.4 | 16.7 |
| Cycle 5 Day 1: Q1d: PICC | 41.7 | 0 |
| Cycle 5 Day 1: Q1d: Port-a-Cath | 33.3 | 83.3 |
| Cycle 5 Day 1: Q1d: Tunneled Central Venous Catheter | 5.6 | 0 |
| Cycle 5 Day 1: Q1e: Within 7 Days Prior Today | 21.1 | 7.4 |
| Cycle 5 Day 1: Q1e: > 7 < 14 Days Prior Today | 10.5 | 11.1 |
| Cycle 5 Day 1: Q1e: > 14 < 30 Days Prior Today | 15.8 | 29.6 |
| Cycle 5 Day 1: Q1e: Other | 52.6 | 51.9 |
| Cycle 6 Day 1: Q1a: PH FDC SC | 0.9 | 100 |
| Cycle 6 Day 1: Q1a: P+H IV | 99.1 | 0 |
| Cycle 6 Day 1: Q1b: Yes | 34.9 | 40.0 |
| Cycle 6 Day 1: Q1b: No | 65.1 | 60.0 |
| Cycle 6 Day 1: Q1c: Port-a-cath | 2.8 | 0 |
| Cycle 6 Day 1: Q1c: Peripheral Vein Cannulation | 94.4 | 100 |
| Cycle 6 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 6 Day 1: Q1c: Central Venous Catheter | 2.8 | 0 |
| Cycle 6 Day 1: Q1d: Central Venous Catheter | 16.2 | 0 |
| Cycle 6 Day 1: Q1d: PICC | 43.2 | 14.3 |
| Cycle 6 Day 1: Q1d: Port-a-Cath | 32.4 | 85.7 |
| Cycle 6 Day 1: Q1d: Tunneled Central Venous Catheter | 8.1 | 0 |
| Cycle 6 Day 1: Q1e: Within 7 Days Prior Today | 25.0 | 6.5 |
| Cycle 6 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 9.7 |
| Cycle 6 Day 1: Q1e: > 14 < 30 Days Prior Today | 15.0 | 29.0 |
| Cycle 6 Day 1: Q1e: Other | 60.0 | 54.8 |
| Cycle 7 Day 1: Q1a: PH FDC SC | 0 | 100 |
| Cycle 7 Day 1: Q1a: P+H IV | 100 | 0 |
| Cycle 7 Day 1: Q1b: Yes | 28.1 | 66.7 |
| Cycle 7 Day 1: Q1b: No | 71.9 | 33.3 |
| Cycle 7 Day 1: Q1c: Peripheral Vein Cannulation | 97.6 | 50.0 |
| Cycle 7 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 7 Day 1: Q1c: Central Venous Catheter | 2.4 | 50.0 |
| Cycle 7 Day 1: Q1d: Central Venous Catheter | 6.3 | 0 |
| Cycle 7 Day 1: Q1d: PICC | 50.0 | 20.0 |
| Cycle 7 Day 1: Q1d: Port-a-Cath | 25.0 | 80.0 |
| Cycle 7 Day 1: Q1d: Tunneled Central Venous Catheter | 18.8 | 0 |
| Cycle 7 Day 1: Q1e: Within 7 Days Prior Today | 38.5 | 11.8 |
| Cycle 7 Day 1: Q1e: > 7 < 14 Days Prior Today | 0 | 17.6 |
| Cycle 7 Day 1: Q1e: > 14 < 30 Days Prior Today | 15.4 | 5.9 |
| Cycle 7 Day 1: Q1e: Other | 46.2 | 64.7 |
| Cycle 8 Day 1: Q1a: PH FDC SC | 0 | 100 |
| Cycle 8 Day 1: Q1a: P+H IV | 100 | 0 |
| Cycle 8 Day 1: Q1b: Yes | 33.3 | 0 |
| Cycle 8 Day 1: Q1b: No | 66.7 | 100 |
| Cycle 8 Day 1: Q1c: Peripheral Vein Cannulation | 97.4 | 100 |
| Cycle 8 Day 1: Q1c: PICC | 0 | 0 |
| Cycle 8 Day 1: Q1c: Central Venous Catheter | 2.6 | 0 |
| Cycle 8 Day 1: Q1d: Central Venous Catheter | 10.5 | 0 |
| Cycle 8 Day 1: Q1d: PICC | 47.4 | 100 |
| Cycle 8 Day 1: Q1d: Port-a-Cath | 31.6 | 0 |
| Cycle 8 Day 1: Q1d: Tunneled Central Venous Catheter | 10.5 | 0 |
| Cycle 8 Day 1: Q1e: Within 7 Days Prior Today | 20.0 | 14.3 |
| Cycle 8 Day 1: Q1e: > 7 < 14 Days Prior Today | 13.3 | 28.6 |
| Cycle 8 Day 1: Q1e: > 14 < 30 Days Prior Today | 20.0 | 0 |
| Cycle 8 Day 1: Q1e: Other | 46.7 | 57.1 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1c: If new IV access was needed for this cycle of treatment, how long (in minutes) this took to set up? Q1f: How long (in minutes) did it take to administer the treatment (P+H IV or PH FDC SC)? Q1g: How long (in minutes) was the participant in the Treatment Area in total? Percentages have been rounded off.
| minutes | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Cycle 1 Day 1: Q1c | 5.0 (1 to 150) | 5.0 (1 to 308) |
| Cycle 1 Day 1: Q1f | 180.0 (60 to 390) | 8.0 (5 to 30) |
| Cycle 1 Day 1: Q1g | 420.0 (120 to 520) | 180.0 (8 to 424) |
| Cycle 2 Day 1: Q1c | 5.0 (1 to 18) | 5.0 (2 to 6) |
| Cycle 2 Day 1: Q1f | 82.5 (5 to 360) | 5.0 (5 to 190) |
| Cycle 2 Day 1: Q1g | 300.0 (90 to 503) | 180.0 (5 to 330) |
| Cycle 3 Day 1: Q1c | 5.0 (1 to 20) | 10.0 (5 to 10) |
| Cycle 3 Day 1: Q1f | 90.0 (5 to 360) | 5.0 (3 to 159) |
| Cycle 3 Day 1: Q1g | 280.0 (90 to 500) | 180.0 (6 to 480) |
| Cycle 4 Day 1: Q1c | 5.0 (2 to 20) | 6.5 (5 to 10) |
| Cycle 4 Day 1: Q1f | 90.0 (14 to 365) | 5.0 (3 to 15) |
| Cycle 4 Day 1: Q1g | 270.0 (30 to 560) | 170.0 (6 to 480) |
| Cycle 5 Day 1: Q1c | 5.0 (1 to 150) | 5.0 (1 to 10) |
| Cycle 5 Day 1: Q1f | 145.0 (8 to 360) | 8.0 (4 to 250) |
| Cycle 5 Day 1: Q1g | 294.0 (30 to 552) | 150.0 (5 to 420) |
| Cycle 6 Day 1: Q1c | 5.0 (1 to 25) | 5.0 (2 to 5) |
| Cycle 6 Day 1: Q1f | 90.0 (8 to 360) | 5.0 (4 to 80) |
| Cycle 6 Day 1: Q1g | 260.0 (35 to 510) | 150.0 (5 to 370) |
| Cycle 7 Day 1: Q1c | 5.0 (1 to 30) | 3.0 (3 to 3) |
| Cycle 7 Day 1: Q1f | 90.0 (8 to 210) | 5.0 (4 to 75) |
| Cycle 7 Day 1: Q1g | 190.0 (40 to 480) | 115.0 (5 to 360) |
| Cycle 8 Day 1: Q1c | 5.0 (1 to 20) | 5.0 (4 to 8) |
| Cycle 8 Day 1: Q1f | 90.0 (5 to 180) | 5.0 (3 to 25) |
| Cycle 8 Day 1: Q1g | 180.0 (60 to 535) | 120.0 (6 to 345) |
HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Q2 (2a-2e) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Participants may be moved out of the Treatment Area (for infusion treatment) to receive PH FDC SC injections. 2b: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2c: Frees up infusion chairs for participants whose treatments can only be given IV. 2d: Waiting list for any P+H IV treatment at the Treatment Area is reduced. 2e: Staff's work burden is reduced, enhancing work performance. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Q2a: Strongly Disagree | 1.0 | 3.0 |
| Q2a: Disagree | 8.2 | 13.4 |
| Q2a: Neutral | 14.4 | 13.4 |
| Q2a: Agree | 36.1 | 28.7 |
| Q2a: Strongly Agree | 32.0 | 33.5 |
| Q2a: Not Applicable | 8.2 | 7.9 |
| Q2b: Strongly Disagree | 0 | 2.4 |
| Q2b: Disagree | 9.2 | 6.0 |
| Q2b: Neutral | 12.2 | 13.9 |
| Q2b: Agree | 37.8 | 34.3 |
| Q2b: Strongly Agree | 33.7 | 35.5 |
| Q2b: Not Applicable | 7.1 | 7.8 |
| Q2c: Strongly Disagree | 1.0 | 3.0 |
| Q2c: Disagree | 9.2 | 6.0 |
| Q2c: Neutral | 10.2 | 10.8 |
| Q2c: Agree | 32.7 | 35.5 |
| Q2c: Strongly Agree | 39.8 | 37.3 |
| Q2c: Not Applicable | 7.1 | 7.2 |
| Q2d: Strongly Disagree | 0 | 1.8 |
| Q2d: Disagree | 8.2 | 6.0 |
| Q2d: Neutral | 15.3 | 15.7 |
| Q2d: Agree | 34.7 | 37.3 |
| Q2d: Strongly Agree | 35.7 | 31.9 |
| Q2d: Not Applicable | 6.1 | 7.2 |
| Q2e: Strongly Disagree | 0 | 3.6 |
| Q2e: Disagree | 5.1 | 3.6 |
| Q2e: Neutral | 27.6 | 25.5 |
| Q2e: Agree | 26.5 | 27.3 |
| Q2e: Strongly Agree | 34.7 | 32.7 |
| Q2e: Not Applicable | 6.1 | 7.3 |
HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Question 2 (2f to 2j) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2f: More interaction time between HCPs and participants. 2g: Staff have more time for further professional education/development. 2h: Staff has more time for administrative tasks. 2i: Participants on PH FDC SC spend less time in the Treatment Area. 2j: Participants prefer PH FDC SC to P+H IV. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Q2f: Strongly Disagree | 0 | 2.4 |
| Q2f: Disagree | 8.2 | 4.2 |
| Q2f: Neutral | 20.4 | 34.3 |
| Q2f: Agree | 33.7 | 22.3 |
| Q2f: Strongly Agree | 31.6 | 28.9 |
| Q2f: Not Applicable | 6.1 | 7.8 |
| Q2g: Strongly Disagree | 2.0 | 2.4 |
| Q2g: Disagree | 5.1 | 4.8 |
| Q2g: Neutral | 25.5 | 36.7 |
| Q2g: Agree | 31.6 | 22.9 |
| Q2g: Strongly Agree | 29.6 | 25.3 |
| Q2g: Not Applicable | 6.1 | 7.8 |
| Q2h: Strongly Disagree | 0 | 1.2 |
| Q2h: Disagree | 6.1 | 3.6 |
| Q2h: Neutral | 23.5 | 31.9 |
| Q2h: Agree | 30.6 | 25.9 |
| Q2h: Strongly Agree | 33.7 | 28.9 |
| Q2h: Not Applicable | 6.1 | 8.4 |
| Q2i: Strongly Disagree | 1.0 | 1.8 |
| Q2i: Disagree | 0 | 1.8 |
| Q2i: Neutral | 4.1 | 3.0 |
| Q2i: Agree | 26.8 | 31.9 |
| Q2i: Strongly Agree | 61.9 | 53.0 |
| Q2i: Not Applicable | 6.2 | 8.4 |
| Q2j: Strongly Disagree | 1.0 | 0.6 |
| Q2j: Disagree | 1.0 | 1.8 |
| Q2j: Neutral | 20.6 | 21.7 |
| Q2j: Agree | 35.1 | 31.3 |
| Q2j: Strongly Agree | 35.1 | 32.5 |
| Q2j: Not Applicable | 7.2 | 12.0 |
HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Questions 3 to 11 of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care at your institution? Q5: Which required less time to administer (excluding observation period)? Q6: Which required less use of institutional resources (e.g., staff time, facility costs, equipment use)? Q7: Which required less time to administer all the treatment (including IV chemotherapy)? Q8: Which allowed for attending to more participants because of time savings from the mode of administration of pertuzumab and trastuzumab? Q9: During the NP you had to administer IV chemotherapy through participant's IV access. You prefer to accompany IV chemotherapy with? Q10: Which was preferred by participants? Q11: How frequently would you recommend PH FDC SC administration to your participants in the future? Percentages were rounded off.
| percentage of HCPs | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Q3: P+H IV | 8.0 | 1.2 |
| Q3: PH FDC SC | 68.2 | 83.9 |
| Q3: No Difference | 13.6 | 8.7 |
| Q3: Unsure | 10.2 | 6.2 |
| Q4: P+H IV | 5.7 | 1.9 |
| Q4: PH FDC SC | 69.3 | 82.1 |
| Q4: No Difference | 22.7 | 13.0 |
| Q4: Unsure | 2.3 | 3.1 |
| Q5: P+H IV | 0 | 0.6 |
| Q5: PH FDC SC | 92.0 | 97.5 |
| Q5: No Difference | 8.0 | 1.9 |
| Q5: Unsure | 0 | 0 |
| Q6: P+H IV | 0 | 0.6 |
| Q6: PH FDC SC | 83.0 | 88.9 |
| Q6: No Difference | 17.0 | 10.5 |
| Q6: Unsure | 0 | 0 |
| Q7: P+H IV | 1.1 | 0 |
| Q7: PH FDC SC | 96.6 | 98.1 |
| Q7: No Difference | 2.3 | 1.9 |
| Q7: Unsure | 0 | 0 |
| Q8: P+H IV | 0 | 0.6 |
| Q8: PH FDC SC | 73.6 | 82.7 |
| Q8: No Difference | 26.4 | 16.7 |
| Q8: Unsure | 0 | 0 |
| Q9: P+H IV | 12.6 | 8.7 |
| Q9: PH FDC SC | 73.6 | 73.9 |
| Q9: No Difference | 13.8 | 17.4 |
| Q9: Unsure | 0 | 0 |
| Q10: P+H IV | 7.9 | 1.2 |
| Q10: PH FDC SC | 66.3 | 73.5 |
| Q10: No Difference | 10.1 | 7.4 |
| Q10: Unsure | 15.7 | 17.9 |
| Q11: Always | 75.3 | 79.1 |
| Q11: Sometimes | 24.7 | 19.0 |
| Q11: Never | 0 | 1.9 |
pCR was defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0), according to the current American Joint Committee on Cancer (AJCC) staging system classification. Percentages were rounded off.
| percentage of participants | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Percentage of Participants Who Achieved pCR Post-surgery | 60.2 | 60.9 |
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), global health status/quality of life (GHS/QoL) \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
| score on a scale | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Baseline - GHS/QoL | 79.86 ± 18.40 | 75.97 ± 20.92 |
| Change at Cycle 6 Day 1 - GHS/QoL | -9.43 ± 21.27 | -7.40 ± 24.64 |
| Change at Cycle 8 Day 1 - GHS/QoL | -10.42 ± 19.73 | -11.75 ± 26.78 |
| Baseline - Physical functioning (PF) | 91.65 ± 11.84 | 91.84 ± 12.45 |
| Change at Cycle 6 Day 1 - PF | -12.65 ± 16.18 | -16.01 ± 18.56 |
| Change at Cycle 8 Day 1 - PF | -16.03 ± 19.28 | -13.00 ± 16.25 |
| Baseline - Role Functioning (RF) | 91.88 ± 15.82 | 91.48 ± 19.11 |
| Change at Cycle 6 Day 1 - RF | -15.85 ± 28.78 | -21.18 ± 29.46 |
| Change at Cycle 8 Day 1 - RF | -19.87 ± 27.62 | -14.91 ± 27.98 |
| Baseline - Emotional Functioning (EF) | 73.41 ± 22.13 | 71.45 ± 22.54 |
| Change at Cycle 6 Day 1 - EF | -5.87 ± 26.06 | 1.01 ± 25.20 |
| Change at Cycle 8 Day 1 - EF | 5.29 ± 24.09 | 5.85 ± 25.01 |
| Baseline - Cognitive functioning (CF) | 88.41 ± 19.01 | 88.19 ± 17.62 |
| Change at Cycle 6 Day 1 - CF | -12.02 ± 22.39 | -10.28 ± 23.53 |
| Change at Cycle 8 Day 1 - CF | -9.62 ± 25.21 | -4.74 ± 18.78 |
| Baseline - Social Functioning (SF) | 86.67 ± 22.96 | 84.30 ± 24.56 |
| Change at Cycle 6 Day 1 - SF | -18.03 ± 30.01 | -15.26 ± 32.55 |
| Change at Cycle 8 Day 1 - SF | -14.42 ± 27.82 | -7.54 ± 25.59 |
| Baseline - Fatigue | 15.85 ± 20.29 | 16.44 ± 17.74 |
| Change at Cycle 6 Day 1 - Fatigue | 24.04 ± 26.23 | 27.21 ± 25.91 |
| Change at Cycle 8 Day 1 - Fatigue | 23.29 ± 24.33 | 20.23 ± 24.31 |
| Baseline - Nausea & Vomiting | 4.06 ± 11.60 | 3.36 ± 10.25 |
| Change at Cycle 6 Day 1 - Nausea & Vomiting | 19.95 ± 24.69 | 14.80 ± 22.82 |
| Change at Cycle 8 Day 1 - Nausea & Vomiting | 3.21 ± 20.88 | 4.74 ± 17.64 |
| Baseline - Pain | 12.17 ± 18.25 | 14.13 ± 19.14 |
| Change at Cycle 6 Day 1 - Pain | 14.21 ± 27.53 | 7.79 ± 25.83 |
| Change at Cycle 8 Day 1 - Pain | 11.86 ± 29.21 | 8.07 ± 21.59 |
| Baseline - Dyspnoea | 4.35 ± 14.32 | 6.28 ± 16.45 |
| Change at Cycle 6 Day 1 - Dyspnoea | 8.74 ± 23.49 | 12.46 ± 24.88 |
| Change at Cycle 8 Day 1 - Dyspnoea | 13.46 ± 28.97 | 6.67 ± 23.11 |
| Baseline - Insomnia | 25.22 ± 30.14 | 24.51 ± 28.07 |
| Change at Cycle 6 Day 1 - Insomnia | 4.37 ± 32.48 | 3.12 ± 35.33 |
| Change at Cycle 8 Day 1 - Insomnia | 8.97 ± 40.75 | 9.12 ± 33.84 |
| Baseline - Appetite Loss | 8.41 ± 20.16 | 9.72 ± 20.51 |
| Change at Cycle 6 Day 1 - Appetite Loss | 21.31 ± 32.22 | 23.99 ± 33.89 |
| Change at Cycle 8 Day 1 - Appetite Loss | 16.03 ± 33.97 | 15.09 ± 35.65 |
| Baseline - Constipation | 9.57 ± 21.07 | 9.87 ± 20.56 |
| Change at Cycle 6 Day 1 - Constipation | 7.65 ± 29.44 | 5.61 ± 25.69 |
| Change at Cycle 8 Day 1 - Constipation | 2.61 ± 21.95 | 3.86 ± 24.73 |
| Baseline - Diarrhoea | 3.77 ± 13.07 | 4.93 ± 14.86 |
| Change at Cycle 6 Day 1 - Diarrhoea | 25.68 ± 33.55 | 28.04 ± 34.31 |
| Change at Cycle 8 Day 1 - Diarrhoea | 32.05 ± 26.37 | 27.37 ± 33.68 |
| Baseline - Financial Difficulties | 26.09 ± 34.14 | 23.17 ± 32.67 |
| Change at Cycle 6 Day 1 - Financial Difficulties | 6.01 ± 41.95 | 7.79 ± 35.93 |
| Change at Cycle 8 Day 1 - Financial Difficulties | 6.41 ± 28.80 | -1.40 ± 33.66 |
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
| score on a scale | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Baseline - GHS/QoL | 76.98 ± 17.09 | 71.79 ± 18.63 |
| Change at Cycle 1 Day 1- GHS/QoL | 0.66 ± 13.72 | 0.09 ± 18.57 |
| Change at Cycle 3 Day 1 - GHS/QoL | 2.08 ± 14.53 | 5.15 ± 20.59 |
| Change at Cycle 6 Day 1 - GHS/QoL | -0.57 ± 16.61 | 2.48 ± 19.99 |
| Baseline - Physical Functioning (PF) | 82.61 ± 15.89 | 80.35 ± 16.20 |
| Change at Cycle 1 Day 1 - PF | 2.50 ± 13.19 | 1.83 ± 14.44 |
| Change at Cycle 3 Day 1 - PF | 2.50 ± 13.65 | 5.99 ± 14.18 |
| Change at Cycle 6 Day 1 - PF | 4.13 ± 16.97 | 2.46 ± 14.99 |
| Baseline - Role Functioning (RF) | 78.35 ± 21.40 | 66.67 ± 29.72 |
| Change at Cycle 1 Day 1 - RF | 4.92 ± 21.61 | 10.62 ± 27.84 |
| Change at Cycle 3 Day 1 - RF | 6.25 ± 23.61 | 17.23 ± 31.33 |
| Change at Cycle 6 Day 1 - RF | 9.66 ± 23.53 | 16.07 ± 31.73 |
| Baseline - Emotional Functioning (EF) | 82.22 ± 19.31 | 76.65 ± 22.61 |
| Change at Cycle 1 Day 1 - EF | -1.22 ± 18.44 | 0.34 ± 23.55 |
| Change at Cycle 3 Day 1 - EF | 2.27 ± 16.75 | 3.46 ± 18.84 |
| Change at Cycle 6 Day 1 - EF | -0.95 ± 21.86 | 0.60 ± 19.86 |
| Baseline - Cognitive Functioning (CF) | 84.54 ± 21.14 | 79.51 ± 24.24 |
| Change at Cycle 1 Day 1 - CF | -3.37 ± 21.05 | 0.00 ± 22.50 |
| Change at Cycle 3 Day 1 - CF | -2.08 ± 21.11 | 1.12 ± 21.14 |
| Change at Cycle 6 Day 1 - CF | -2.65 ± 22.30 | 0.00 ± 24.54 |
| Baseline - Social Functioning (SF) | 80.58 ± 22.65 | 70.49 ± 25.87 |
| Change at Cycle 1 Day 1 - SF | 1.69 ± 22.34 | 6.59 ± 27.76 |
| Change at Cycle 3 Day 1 - SF | 1.70 ± 20.69 | 9.74 ± 25.23 |
| Change at Cycle 6 Day 1 - SF | 0.95 ± 21.64 | 9.92 ± 25.89 |
| Baseline - Fatigue | 26.92 ± 21.92 | 31.83 ± 23.56 |
| Change at Cycle 1 Day 1 - Fatigue | -3.62 ± 17.55 | -0.61 ± 24.31 |
| Change at Cycle 3 Day 1 - Fatigue | -3.66 ± 18.66 | -7.99 ± 21.65 |
| Change at Cycle 6 Day 1 - Fatigue | -4.42 ± 24.09 | -4.37 ± 23.84 |
| Baseline - Nausea & Vomiting | 4.64 ± 10.96 | 5.38 ± 11.47 |
| Change at Cycle 1 Day 1 - Nausea & Vomiting | -0.95 ± 11.95 | 1.83 ± 14.79 |
| Change at Cycle 3 Day 1 - Nausea & Vomiting | -0.57 ± 11.43 | -1.31 ± 10.43 |
| Change at Cycle 6 Day 1 - Nausea & Vomiting | -0.95 ± 12.21 | 0.99 ± 12.77 |
| Baseline - Pain | 22.51 ± 20.84 | 28.82 ± 26.10 |
| Change at Cycle 1 Day 1 - Pain | -5.30 ± 21.82 | -7.14 ± 23.46 |
| Change at Cycle 3 Day 1 - Pain | -6.37 ± 20.18 | -9.74 ± 25.97 |
| Change at Cycle 6 Day 1 - Pain | -6.06 ± 23.59 | -8.73 ± 27.19 |
| Baseline - Dyspnoea | 7.56 ± 17.68 | 8.68 ± 17.60 |
| Change at Cycle 1 Day 1 - Dyspnoea | 1.89 ± 20.44 | 0.73 ± 21.65 |
| Change at Cycle 3 Day 1 - Dyspnoea | 0.00 ± 20.84 | 0.75 ± 21.89 |
| Change at Cycle 6 Day 1 - Dyspnoea | 0.38 ± 17.86 | 0.40 ± 21.64 |
| Baseline - Insomnia | 25.09 ± 27.23 | 28.13 ± 32.92 |
| Change at Cycle 1 Day 1 - Insomnia | -1.12 ± 27.27 | 4.40 ± 31.51 |
| Change at Cycle 3 Day 1 - Insomnia | 0.00 ± 27.68 | -3.00 ± 34.68 |
| Change at Cycle 6 Day 1 - Insomnia | 0.76 ± 28.58 | 0.00 ± 37.67 |
| Baseline - Appetite loss | 10.65 ± 18.35 | 11.81 ± 21.07 |
| Change at Cycle 1 Day 1 - Appetite loss | 2.27 ± 27.59 | 2.56 ± 29.07 |
| Change at Cycle 3 Day 1 - Appetite loss | -0.38 ± 25.01 | 0.00 ± 25.62 |
| Change at Cycle 6 Day 1 - Appetite loss | -1.14 ± 24.47 | 0.00 ± 25.87 |
| Baseline - Constipation | 13.75 ± 22.95 | 13.89 ± 22.51 |
| Change at Cycle 1 Day 1 - Constipation | -2.62 ± 21.45 | 0.00 ± 19.25 |
| Change at Cycle 3 Day 1 - Constipation | -4.92 ± 23.99 | 0.00 ± 25.62 |
| Change at Cycle 6 Day 1 - Constipation | -3.79 ± 27.88 | 1.98 ± 21.55 |
| Baseline - Diarrhoea | 12.37 ± 25.15 | 12.15 ± 22.75 |
| Change at Cycle 1 Day 1 - Diarrhoea | 0.00 ± 26.74 | 4.76 ± 33.17 |
| Change at Cycle 3 Day 1 - Diarrhoea | -0.38 ± 24.50 | 2.25 ± 32.10 |
| Change at Cycle 6 Day 1 - Diarrhoea | 1.89 ± 29.62 | 4.76 ± 32.37 |
| Baseline - Financial difficulties | 28.18 ± 34.14 | 32.29 ± 34.35 |
| Change at Cycle 1 Day 1 - Financial Difficulties | -6.37 ± 24.04 | -4.40 ± 28.20 |
| Change at Cycle 3 Day 1 - Financial Difficulties | -4.92 ± 27.00 | -6.37 ± 29.68 |
| Change at Cycle 6 Day 1 - Financial Difficulties | -2.65 ± 27.32 | -6.35 ± 30.82 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: Where was the treatment prepared? Q1c: Which healthcare professionals were involved in the treatment preparation processes? The 4 available response options for Q1a were: Participant's home, Hospital pharmacy, Day oncology unit, or Other. The 5 available response options for Q1c were: Physician, Nurse, Pharmacist, All of them or Other. Percentages were rounded off.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Cycle 3 Day 1: Q1a: Participant's Home | 0 | 90.6 |
| Cycle 3 Day 1: Q1a: Hospital Pharmacy | 72.6 | 9.4 |
| Cycle 3 Day 1: Q1a: Day Oncology Unit | 17.7 | 0 |
| Cycle 3 Day 1: Q1a: Other | 9.7 | 0 |
| Cycle 3 Day 1: Q1c: Physician | 0 | 11.7 |
| Cycle 3 Day 1: Q1c: Nurse | 35.1 | 75.3 |
| Cycle 3 Day 1: Q1c: Pharmacist | 59.7 | 7.8 |
| Cycle 3 Day 1: Q1c: All of Them | 2.6 | 2.6 |
| Cycle 3 Day 1: Q1c: Other | 2.6 | 2.6 |
| Cycle 6 Day 1: Q1a: Participant's Home | 95.2 | 0 |
| Cycle 6 Day 1: Q1a: Hospital Pharmacy | 4.8 | 71.6 |
| Cycle 6: Q1a: Day Oncology Unit | 0 | 20.9 |
| Cycle 6 Day 1: Q1a: Other | 0 | 7.5 |
| Cycle 6 Day 1: Q1c: Physician | 5.1 | 2.8 |
| Cycle 6 Day 1: Q1c: Nurse | 88.5 | 29.2 |
| Cycle 6 Day 1: Q1c: Pharmacist | 2.6 | 58.3 |
| Cycle 6 Day 1: Q1c: All of them | 2.6 | 5.6 |
| Cycle 6 Day 1: Q1c: Other | 1.3 | 4.2 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following parts of question Q1b: Q1b(1): How long did it take to prepare the treatment for use? Q1b(2): Time from the preparation place to reach the participant's home.
| minutes | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Cycle 3 Day 1: Q1b(1) | 5.0 (1 to 33) | 5.0 (1 to 30) |
| Cycle 3 Day 1: Q1b(2) | 5.0 (0 to 35) | 1.0 (0 to 70) |
| Cycle 6 Day 1: Q1b(1) | 5.0 (1 to 30) | 4.0 (1 to 15) |
| Cycle 6 Day 1: Q1b(2) | 0.0 (0 to 60) | 3.0 (0 to 30) |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the questions 2, 3 and 4 of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant´s home, please indicate how strongly you agree or disagree with each of the following statements: 2a: Staff will have increased availability for other tasks in the hospital´s pharmacy. 2b: Administrative procedures related to PH FDC SC will require less time. 2c: Number of preparation steps and staff time commitment are reduced. The 5 response options were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree or Not applicable. Q3: Which took less time? Q4: Which required less use of institutional resources? The 4 available options were: Participant's home, In hospital, No difference, or Unsure. Percentages were rounded off.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Q2a: Strongly Disagree | 2.5 | 1.3 |
| Q2a: Disagree | 0 | 18.7 |
| Q2a: Neutral | 6.2 | 16.0 |
| Q2a: Agree | 43.2 | 21.3 |
| Q2a: Strongly Agree | 38.3 | 37.3 |
| Q2a: Not Applicable | 9.9 | 5.3 |
| Q2b: Strongly Disagree | 4.9 | 2.7 |
| Q2b: Disagree | 2.5 | 24.3 |
| Q2b: Neutral | 13.6 | 13.5 |
| Q2b: Agree | 33.3 | 18.9 |
| Q2b: Strongly Agree | 35.8 | 35.1 |
| Q2b: Not Applicable | 9.9 | 5.4 |
| Q2c: Strongly Disagree | 2.5 | 0 |
| Q2c: Disagree | 2.5 | 18.9 |
| Q2c: Neutral | 6.2 | 21.6 |
| Q2c: Agree | 39.5 | 16.2 |
| Q2c: Strongly Agree | 38.3 | 37.8 |
| Q2c: Not Applicable | 11.1 | 5.4 |
| Q3: Participant's Home | 59.5 | 22.2 |
| Q3: In hospital | 2.5 | 36.1 |
| Q3: No Difference | 11.4 | 31.9 |
| Q3: Unsure | 26.6 | 9.7 |
| Q4: Participant's Home | 73.4 | 38.9 |
| Q4: In hospital | 5.1 | 36.1 |
| Q4: No Difference | 8.9 | 19.4 |
| Q4: Unsure | 12.7 | 5.6 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: How long did it take to travel to the participant's home to administer PH FDC SC? Q1b: How long did it take for the participant to travel to the hospital to receive PH FDC SC? Q1c: How long did it take to administer PH FDC SC? Q1d: How long was the participant treatment time? Q1e: How much time did the participant spend in hospital? Q1f: How much time did you spend at the participant's home? From arrival to departure time.
| minutes | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Cycle 3 Day 1: Q1a | 82.5 (60 to 105) | 60.0 (11 to 540) |
| Cycle 3 Day 1: Q1b | 60.0 (10 to 420) | 60.0 (10 to 660) |
| Cycle 3 Day 1: Q1c | 5.0 (5 to 13) | 5.0 (5 to 30) |
| Cycle 3 Day 1: Q1d | 30.0 (5 to 540) | 75.0 (5 to 240) |
| Cycle 3 Day 1: Q1e | 120.0 (25 to 586) | 180.0 (70 to 360) |
| Cycle 3 Day 1: Q1f | — | 90.0 (40 to 175) |
| Cycle 6 Day 1: Q1a | 65.0 (5 to 480) | 85.0 (50 to 180) |
| Cycle 6 Day 1: Q1b | 60.0 (15 to 480) | 60.0 (5 to 660) |
| Cycle 6 Day 1: Q1c | 5.0 (5 to 30) | 5.0 (5 to 10) |
| Cycle 6 Day 1: Q1d | 90.0 (8 to 165) | 30.0 (5 to 240) |
| Cycle 6 Day 1: Q1e | 120.0 (50 to 600) | 120.0 (25 to 480) |
| Cycle 6 Day 1: Q1f | 90.0 (20 to 165) | 90.0 (90 to 90) |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1g. Does the participant still have implanted IV access? The 2 available responses were: Yes or No. Q1h: If question 1g was answered 'No', when was the IV access removed? The 3 available responses were: After surgery and before initiating adjuvant treatment; After initiating adjuvant treatment, or Not applicable. Q1i: If question 1g was answered 'Yes', what is the main reason to keep the IV access? The 5 available responses were: Local protocol; Risk of recurrence; Participant preference; Not applicable, or Other. Percentages were rounded off.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Cycle 3 Day 1: Q1g: Yes | 35.6 | 14.5 |
| Cycle 3 Day 1: Q1g: No | 64.4 | 85.5 |
| Cycle 3 Day 1: Q1h: After Surgery and Before Adjuvant Treatment | 7.1 | 4.3 |
| Cycle 3 Day 1: Q1h: After Initiating Adjuvant Treatment | 7.1 | 10.6 |
| Cycle 3 Day 1: Q1h: Not Applicable | 85.7 | 85.1 |
| Cycle 3 Day 1: Q1i: Local Protocol | 45.0 | 21.4 |
| Cycle 3 Day 1: Q1i: Risk of Recurrence | 10.0 | 14.3 |
| Cycle 3 Day 1: Q1i: Participant Preference | 25.0 | 14.3 |
| Cycle 3 Day 1: Q1i: Not Applicable | 15.0 | 50.0 |
| Cycle 3 Day 1: Q1i: Other | 5.0 | 0 |
| Cycle 6 Day 1: Q1g: Yes | 23.7 | 23.0 |
| Cycle 6 Day 1: Q1g: No | 76.3 | 77.0 |
| Cycle 6 Day 1: Q1h: After Surgery and Before Adjuvant Treatment | 10.4 | 6.4 |
| Cycle 6 Day 1: Q1h: After Initiating Adjuvant Treatment | 0 | 6.4 |
| Cycle 6 Day 1: Q1h: Not Applicable | 89.6 | 87.2 |
| Cycle 6 Day 1: Q1i: Local Protocol | 27.6 | 42.9 |
| Cycle 6 Day 1: Q1i: Risk of Recurrence | 3.4 | 4.8 |
| Cycle 6 Day 1: Q1i: Participant Preference | 13.8 | 4.8 |
| Cycle 6 Day 1: Q1i: Not Applicable | 51.7 | 38.1 |
| Cycle 6 Day 1: Q1i: Other | 3.4 | 9.5 |
HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1j: How long do you keep implanted IV access in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer participants with pCR following surgery in your institution? The 5 available responses were: \<12 months, ≥12 months, 18 months, \<24 months, ≥24 months. Q1k: When is the decision point for you to decide to remove IV access for early HER2+ breast cancer participants? The 6 available responses were: Before surgery, After surgery, After PCR results, After completion of full adjuvant therapy, After completion of IV antineoplastic within adjuvant therapy, and Other. Q1l: Do you consider it necessary to keep implanted IV access knowing that the participant's treatment will be SC until the full 18 cycles? The 3 available responses were: Yes, No, and Unsure. Percentages were rounded off.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Q1j: <12 Months | 10.7 | 27.0 |
| Q1j: ≥12 Months | 28.6 | 16.2 |
| Q1j: 18 Months | 14.3 | 16.2 |
| Q1j: <24 Months | 3.6 | 8.1 |
| Q1j: ≥24 Months | 42.9 | 32.4 |
| Q1k: Before Surgery | 0 | 2.6 |
| Q1k: After Surgery | 2.3 | 10.3 |
| Q1k: After PCR Results | 15.9 | 20.5 |
| Q1k: After Completion of Full Adjuvant Therapy | 15.9 | 28.2 |
| Q1k: After Completion of IV Antineoplastic Within Adjuvant Therapy | 29.5 | 5.1 |
| Q1k: Other | 36.4 | 33.3 |
| Q1l: Yes | 11.9 | 37.2 |
| Q1l: No | 35.7 | 37.2 |
| Q1l: Unsure | 52.4 | 25.6 |
HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following question of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant's home, please indicate how strongly you agree/disagree with each of the following statements: 2a: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2b: Frees up infusion chairs or outpatient procedure rooms used to administer SC injections. 2c: Waiting list for infusion chairs or outpatient procedure rooms is reduced. 2d: Staff's work burden is reduced, enhancing work performance. 2e: More interaction time between HCPs and participants on IV treatment. 2f: Staff has more time for administrative tasks. 2g: Participants will spend less time in hospital. 2h: Participants prefer PH FDC SC at home. The 6 available responses were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree, \& Not applicable.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Q2a: Strongly Disagree | 6.3 | 0 |
| Q2a: Disagree | 0 | 1.3 |
| Q2a: Neutral | 6.3 | 8.0 |
| Q2a: Agree | 30.4 | 41.3 |
| Q2a: Strongly Agree | 55.7 | 45.3 |
| Q2a: Not Applicable | 1.3 | 4.0 |
| Q2b: Strongly Disagree | 6.4 | 1.3 |
| Q2b: Disagree | 0 | 5.3 |
| Q2b: Neutral | 7.7 | 6.7 |
| Q2b: Agree | 29.5 | 33.3 |
| Q2b: Strongly Agree | 55.1 | 49.3 |
| Q2b: Not Applicable | 1.3 | 4.0 |
| Q2c: Strongly Disagree | 7.7 | 2.7 |
| Q2c: Disagree | 0 | 1.3 |
| Q2c: Neutral | 0 | 5.3 |
| Q2c: Agree | 33.3 | 33.3 |
| Q2c: Strongly Agree | 57.7 | 53.3 |
| Q2c: Not Applicable | 1.3 | 4.0 |
| Q2d: Strongly Disagree | 6.5 | 0 |
| Q2d: Disagree | 3.9 | 9.3 |
| Q2d: Neutral | 14.3 | 14.7 |
| Q2d: Agree | 27.3 | 25.3 |
| Q2d: Strongly Agree | 46.8 | 42.7 |
| Q2d: Not Applicable | 1.3 | 8.0 |
| Q2e: Strongly Disagree | 6.4 | 0 |
| Q2e: Disagree | 2.6 | 2.7 |
| Q2e: Neutral | 19.2 | 20.0 |
| Q2e: Agree | 26.9 | 33.3 |
| Q2e: Strongly Agree | 43.6 | 33.3 |
| Q2e: Not Applicable | 1.3 | 10.7 |
| Q2f: Strongly Disagree | 7.7 | 0 |
| Q2f: Disagree | 2.6 | 4.0 |
| Q2f: Neutral | 9.0 | 25.3 |
| Q2f: Agree | 32.1 | 22.7 |
| Q2f: Strongly Agree | 47.4 | 40.0 |
| Q2f: Not Applicable | 1.3 | 8.0 |
| Q2g: Strongly Disagree | 6.4 | 0 |
| Q2g: Disagree | 0 | 1.3 |
| Q2g: Neutral | 0 | 6.7 |
| Q2g: Agree | 24.4 | 32.0 |
| Q2g: Strongly Agree | 67.9 | 56.0 |
| Q2g: Not Applicable | 1.3 | 4.0 |
| Q2h: Strongly Disagree | 6.5 | 2.7 |
| Q2h: Disagree | 3.9 | 18.7 |
| Q2h: Neutral | 15.6 | 28.0 |
| Q2h: Agree | 23.4 | 17.3 |
| Q2h: Strongly Agree | 49.4 | 29.3 |
| Q2h: Not Applicable | 1.3 | 4.0 |
HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care? Q5: Which required less use of institutional resources? Q6: Which was preferred by participants? The 4 responses available were: Participant's home, In hospital, No difference, and Unsure. Q7: How frequently would you recommend PH FDC SC at home to your participants in the future? The 3 responses available were: Always, Sometimes, and Never. Percentages were rounded off.
| percentage of HCPs | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Q3: Participant's Home | 84.0 | 45.9 |
| Q3: In Hospital | 7.4 | 40.5 |
| Q3: No Difference | 6.2 | 6.8 |
| Q3: Unsure | 2.5 | 6.8 |
| Q4: Participant's Home | 80.2 | 28.4 |
| Q4: In Hospital | 7.4 | 52.7 |
| Q4: No Difference | 6.2 | 12.2 |
| Q4: Unsure | 6.2 | 6.8 |
| Q5: Participant's Home | 67.9 | 40.5 |
| Q5: In Hospital | 6.2 | 27.0 |
| Q5: No Difference | 17.3 | 16.2 |
| Q5: Unsure | 8.6 | 16.2 |
| Q6: Participant's Home | 79.0 | 41.9 |
| Q6: In Hospital | 11.1 | 44.6 |
| Q6: No Difference | 6.2 | 6.8 |
| Q6: Unsure | 3.7 | 6.8 |
| Q7: Always | 80.2 | 43.8 |
| Q7: Sometimes | 17.3 | 43.8 |
| Q7: Never | 2.5 | 12.3 |
EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.
Results for this outcome have not been posted.
The percentage of participants who chose to receive PH FDC SC in the home setting or in the hospital setting during the treatment continuation period is reported.
| Percentage of participants | Arm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at Home | Arm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital |
|---|---|---|
| Choice of Home Setting | 68.8 | 54.3 |
| Choice of Hospital Setting | 31.2 | 45.7 |
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in left ventricular ejection fraction (LVEF) of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; congestive heart failure (CHF). AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
| Participants | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| AEs | 113 | 227 |
| SAEs | 19 | 43 |
| Grade ≥ 3 AEs | 46 | 103 |
| Cardiac AEs | 1 | 3 |
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.
| Participants | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC |
|---|---|---|
| Neoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs | 1 | 8 |
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
| Participants | Adjuvant Cross-Over Period: PH FDC SC in Hospital | Adjuvant Cross-Over Period: PH FDC SC at Home |
|---|---|---|
| AEs | 99 | 89 |
| SAEs | 1 | 1 |
| Cardiac AEs | 1 | 2 |
| Grade ≥3 AEs | 6 | 3 |
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.
| Participants | Adjuvant Cross-Over Period: PH FDC SC in Hospital | Adjuvant Cross-Over Period: PH FDC SC at Home |
|---|---|---|
| Adjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs | 2 | 2 |
AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinue study due to AEs will be reported.
Results for this outcome have not been posted.
Collected over From initiation of study treatment until 28 days after the last treatment cycle (Neoadjuvant phase: up to 7.4 months; Adjuvant phase: up to 12.3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A, Neoadjuvant Phase: P+H IV | 0/115 (0%) | 19/115 (16.5%) | 113/115 (98.3%) |
| Arm B, Neoadjuvant Phase: PH FDC SC | 4/228 (1.8%) | 43/228 (18.9%) | 222/228 (97.4%) |
| Adjuvant Run-in Phase: PH FDC SC in Hospital | 0/194 (0%) | 3/194 (1.5%) | 84/194 (43.3%) |
| Adjuvant Cross-Over Phase: PH FDC SC in Hospital | 0/190 (0%) | 1/190 (0.5%) | 77/190 (40.5%) |
| Adjuvant Cross-Over Phase: PH FDC SC at Home | 0/191 (0%) | 1/191 (0.5%) | 64/191 (33.5%) |
| Adjuvant Continuation Phase: PH FDC SC in Hospital | 0/84 (0%) | 1/84 (1.2%) | 26/84 (31%) |
| Adjuvant Continuation Phase: PH FDC SC at Home | 0/114 (0%) | 0/114 (0%) | 31/114 (27.2%) |
| Arm E, Adjuvant Phase: Trastuzumab Emtansine IV | 1/117 (0.9%) | 9/117 (7.7%) | 107/117 (91.5%) |
| Event | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Adjuvant Cross-Over Phase: PH FDC SC in Hospital | Adjuvant Cross-Over Phase: PH FDC SC at Home | Adjuvant Continuation Phase: PH FDC SC in Hospital | Adjuvant Continuation Phase: PH FDC SC at Home | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/115 | 7/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/115 | 7/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 1/117 |
| AnaemiaBlood and lymphatic system disorders | 1/115 | 4/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| NeutropeniaBlood and lymphatic system disorders | 2/115 | 4/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| Postoperative wound infectionInfections and infestations | 2/115 | 0/228 | 1/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| Neutrophil count decreasedInvestigations | 2/115 | 3/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/115 | 1/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/115 | 3/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 2/117 |
| NauseaGastrointestinal disorders | 0/115 | 3/228 | 0/194 | 0/190 | 0/191 | 0/84 | 0/114 | 0/117 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/115 | 0/228 | 0/194 | 0/190 | 0/191 | 1/84 | 0/114 | 0/117 |
| Event | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Adjuvant Run-in Phase: PH FDC SC in Hospital | Adjuvant Cross-Over Phase: PH FDC SC in Hospital | Adjuvant Cross-Over Phase: PH FDC SC at Home | Adjuvant Continuation Phase: PH FDC SC in Hospital | Adjuvant Continuation Phase: PH FDC SC at Home | Arm E, Adjuvant Phase: Trastuzumab Emtansine IV |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 72/115 | 147/228 | 12/194 | 9/190 | 7/191 | 3/84 | 6/114 | 7/117 |
| NauseaGastrointestinal disorders | 64/115 | 136/228 | 5/194 | 2/190 | 2/191 | 1/84 | 3/114 | 18/117 |
| AlopeciaSkin and subcutaneous tissue disorders | 57/115 | 124/228 | 3/194 | 1/190 | 0/191 | 0/84 | 0/114 | 3/117 |
| AnaemiaBlood and lymphatic system disorders | 61/115 | 96/228 | 0/194 | 5/190 | 1/191 | 1/84 | 2/114 | 20/117 |
| FatigueGeneral disorders | 41/115 | 86/228 | 9/194 | 6/190 | 2/191 | 0/84 | 0/114 | 17/117 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/115 | 23/228 | 11/194 | 5/190 | 8/191 | 0/84 | 5/114 | 31/117 |
| NeutropeniaBlood and lymphatic system disorders | 22/115 | 60/228 | 2/194 | 1/190 | 4/191 | 1/84 | 1/114 | 22/117 |
| VomitingGastrointestinal disorders | 25/115 | 57/228 | 1/194 | 1/190 | 1/191 | 1/84 | 2/114 | 6/117 |
| Radiation skin injuryInjury, poisoning and procedural complications | 0/115 | 3/228 | 27/194 | 5/190 | 2/191 | 0/84 | 0/114 | 26/117 |
| Aspartate aminotransferase increasedInvestigations | 11/115 | 20/228 | 1/194 | 1/190 | 1/191 | 1/84 | 0/114 | 26/117 |
Neoadjuvant full analysis set (FASab) included all randomized participants, regardless of whether they received treatment. The HCPs were not enrolled in this study. Hence, no baseline data were planned to be collected for the HCPs responding to HCPQs.
| Age, Continuous(years) | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Total |
|---|---|---|---|
| Mean | 50.9 ± 11.0 | 52.9 ± 11.7 | 52.2 ± 11.5 |
| Sex: Female, Male(Participants) | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Total |
|---|---|---|---|
| Female | 116 | 230 | 346 |
| Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Total |
|---|---|---|---|
| Hispanic or Latino | 52 | 93 | 145 |
| Not Hispanic or Latino | 54 | 118 | 172 |
| Unknown or Not Reported | 10 | 20 | 30 |
| Race (NIH/OMB)(Participants) | Arm A, Neoadjuvant Phase: P+H IV | Arm B, Neoadjuvant Phase: PH FDC SC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 15 | 35 | 50 |
| Asian | 12 | 32 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 23 | 33 |
| White | 66 | 123 | 189 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 10 | 13 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jul 2022 to primary completion in Nov 2024, 28 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf · Pertuzumab
Inflammatory Breast Neoplasms →